Colliers Securities analyst Eugene Mannheimer reiterated a Buy rating on Omnicell (NASDAQ:OMCL) on Tuesday, setting a price target of $135, which is approximately 8.55% above the present share price of $124.37.
Mannheimer expects Omnicell to post earnings per share (EPS) of $0.39 for the first quarter of 2021.
The current consensus among 6 TipRanks analysts is for a Strong Buy rating of shares in Omnicell, with an average price target of $138.17.
The analysts price targets range from a high of $147 to a low of $120.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $249.2 million and a net profit of $20.21 million. The company's market cap is $5.35 billion.
According to TipRanks.com, Colliers Securities analyst Eugene Mannheimer is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 16.1% and a 60.26% success rate.
Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence; platform and interoperability; central pharmacy dispensing; medication adherence; population health; and point of care automation. The company was founded by Randall A. Lipps in September 1992 and is headquartered in Mountain View, CA.